Does the media prefer SDGR or DNTH?

In the previous week, Dianthus Therapeutics had 2 more articles in the media than Schrodinger. MarketBeat recorded 3 mentions for Dianthus Therapeutics and 1 mentions for Schrodinger. Schrodinger's average media sentiment score of 1.40 beat Dianthus Therapeutics' score of 0.00 indicating that Schrodinger is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Schrodinger 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dianthus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer SDGR or ORKA?

In the previous week, Oruka Therapeutics had 1 more articles in the media than Schrodinger. MarketBeat recorded 2 mentions for Oruka Therapeutics and 1 mentions for Schrodinger. Schrodinger's average media sentiment score of 1.40 beat Oruka Therapeutics' score of 0.37 indicating that Schrodinger is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Schrodinger 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oruka Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, ERAS or SDGR?

Schrodinger has higher revenue and earnings than Erasca. Erasca is trading at a lower price-to-earnings ratio than Schrodinger, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Erasca N/A N/A -$124.55M -$0.93 N/A Schrodinger $255.87M 4.87 -$103.26M -$1.41 N/A

Is ERAS or SDGR more profitable?

Erasca has a net margin of 0.00% compared to Schrodinger's net margin of -40.61%. Schrodinger's return on equity of -30.85% beat Erasca's return on equity. Company Net Margins Return on Equity Return on Assets Erasca N/A -35.31% -29.49% Schrodinger -40.61% -30.85% -15.32%

Does the media favor ERAS or SDGR?

In the previous week, Erasca had 24 more articles in the media than Schrodinger. MarketBeat recorded 25 mentions for Erasca and 1 mentions for Schrodinger. Schrodinger's average media sentiment score of 1.40 beat Erasca's score of 0.04 indicating that Schrodinger is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 0 Very Positive mention(s) 2 Positive mention(s) 23 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Schrodinger 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor KNSA or SDGR?

In the previous week, Kiniksa Pharmaceuticals International had 6 more articles in the media than Schrodinger. MarketBeat recorded 7 mentions for Kiniksa Pharmaceuticals International and 1 mentions for Schrodinger. Schrodinger's average media sentiment score of 1.40 beat Kiniksa Pharmaceuticals International's score of 1.23 indicating that Schrodinger is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kiniksa Pharmaceuticals International 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Schrodinger 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Schrodinger (SDGR) Competitors

$16.88 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$16.91 +0.03 (+0.15%)

As of 07/2/2026 07:58 PM Eastern

Compare

SDGR vs. DNTH, ORKA, MANE, ERAS, and KNSA

Should you buy Schrodinger stock or one of its competitors? MarketBeat compares Schrodinger with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Schrodinger include Dianthus Therapeutics (DNTH), Oruka Therapeutics (ORKA), Veradermics (MANE), Erasca (ERAS), and Kiniksa Pharmaceuticals International (KNSA). These companies are all part of the "pharmaceutical products" industry.

How does Schrodinger compare to Dianthus Therapeutics?

Schrodinger (NASDAQ:SDGR) and Dianthus Therapeutics (NASDAQ:DNTH) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

In the previous week, Dianthus Therapeutics had 2 more articles in the media than Schrodinger. MarketBeat recorded 3 mentions for Dianthus Therapeutics and 1 mentions for Schrodinger. Schrodinger's average media sentiment score of 1.40 beat Dianthus Therapeutics' score of 0.00 indicating that Schrodinger is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Schrodinger	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dianthus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Schrodinger has a beta of 1.62, meaning that its stock price is 62% more volatile than the broader market. Comparatively, Dianthus Therapeutics has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market.

Schrodinger has a net margin of -40.61% compared to Dianthus Therapeutics' net margin of -12,998.50%. Dianthus Therapeutics' return on equity of -27.30% beat Schrodinger's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Schrodinger	-40.61%	-30.85%	-15.32%
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%

Schrodinger presently has a consensus target price of $20.25, indicating a potential upside of 19.96%. Dianthus Therapeutics has a consensus target price of $117.82, indicating a potential upside of 24.89%. Given Dianthus Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Dianthus Therapeutics is more favorable than Schrodinger.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Schrodinger	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93

Schrodinger has higher revenue and earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Schrodinger, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Schrodinger	$255.87M	4.87	-$103.26M	-$1.41	N/A
Dianthus Therapeutics	$2.04M	2,528.22	-$162.34M	-$4.13	N/A

79.1% of Schrodinger shares are owned by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are owned by institutional investors. 10.1% of Schrodinger shares are owned by company insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Schrodinger beats Dianthus Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Schrodinger compare to Oruka Therapeutics?

Schrodinger (NASDAQ:SDGR) and Oruka Therapeutics (NASDAQ:ORKA) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.

Oruka Therapeutics has a net margin of 0.00% compared to Schrodinger's net margin of -40.61%. Oruka Therapeutics' return on equity of -26.16% beat Schrodinger's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Schrodinger	-40.61%	-30.85%	-15.32%
Oruka Therapeutics	N/A	-26.16%	-25.00%

Schrodinger has a beta of 1.62, meaning that its share price is 62% more volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.35, meaning that its share price is 135% less volatile than the broader market.

Schrodinger currently has a consensus price target of $20.25, indicating a potential upside of 19.96%. Oruka Therapeutics has a consensus price target of $134.30, indicating a potential upside of 57.61%. Given Oruka Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Oruka Therapeutics is more favorable than Schrodinger.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Schrodinger	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Schrodinger has higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Schrodinger, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Schrodinger	$255.87M	4.87	-$103.26M	-$1.41	N/A
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.94	N/A

In the previous week, Oruka Therapeutics had 1 more articles in the media than Schrodinger. MarketBeat recorded 2 mentions for Oruka Therapeutics and 1 mentions for Schrodinger. Schrodinger's average media sentiment score of 1.40 beat Oruka Therapeutics' score of 0.37 indicating that Schrodinger is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Schrodinger	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oruka Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

79.1% of Schrodinger shares are owned by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are owned by institutional investors. 10.1% of Schrodinger shares are owned by insiders. Comparatively, 23.5% of Oruka Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Schrodinger beats Oruka Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Schrodinger compare to Veradermics?

Schrodinger (NASDAQ:SDGR) and Veradermics (NYSE:MANE) are both pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

Veradermics has a net margin of 0.00% compared to Schrodinger's net margin of -40.61%. Veradermics' return on equity of 0.00% beat Schrodinger's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Schrodinger	-40.61%	-30.85%	-15.32%
Veradermics	N/A	N/A	N/A

Schrodinger presently has a consensus target price of $20.25, indicating a potential upside of 19.96%. Veradermics has a consensus target price of $114.20, indicating a potential downside of 12.06%. Given Schrodinger's higher possible upside, equities research analysts clearly believe Schrodinger is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Schrodinger	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Veradermics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

79.1% of Schrodinger shares are owned by institutional investors. 10.1% of Schrodinger shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Schrodinger had 1 more articles in the media than Veradermics. MarketBeat recorded 1 mentions for Schrodinger and 0 mentions for Veradermics. Schrodinger's average media sentiment score of 1.40 beat Veradermics' score of 0.00 indicating that Schrodinger is being referred to more favorably in the media.

Company	Overall Sentiment
Schrodinger	Positive
Veradermics	Neutral

Veradermics has lower revenue, but higher earnings than Schrodinger. Veradermics is trading at a lower price-to-earnings ratio than Schrodinger, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Schrodinger	$255.87M	4.87	-$103.26M	-$1.41	N/A
Veradermics	N/A	N/A	N/A	-$1.32	N/A

Summary

Schrodinger beats Veradermics on 7 of the 13 factors compared between the two stocks.

How does Schrodinger compare to Erasca?

Erasca (NASDAQ:ERAS) and Schrodinger (NASDAQ:SDGR) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

Erasca has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market. Comparatively, Schrodinger has a beta of 1.62, indicating that its stock price is 62% more volatile than the broader market.

In the previous week, Erasca had 24 more articles in the media than Schrodinger. MarketBeat recorded 25 mentions for Erasca and 1 mentions for Schrodinger. Schrodinger's average media sentiment score of 1.40 beat Erasca's score of 0.04 indicating that Schrodinger is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	0 Very Positive mention(s)	2 Positive mention(s)	23 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Schrodinger	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

67.8% of Erasca shares are held by institutional investors. Comparatively, 79.1% of Schrodinger shares are held by institutional investors. 14.2% of Erasca shares are held by company insiders. Comparatively, 10.1% of Schrodinger shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Schrodinger has higher revenue and earnings than Erasca. Erasca is trading at a lower price-to-earnings ratio than Schrodinger, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A
Schrodinger	$255.87M	4.87	-$103.26M	-$1.41	N/A

Erasca has a net margin of 0.00% compared to Schrodinger's net margin of -40.61%. Schrodinger's return on equity of -30.85% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-35.31%	-29.49%
Schrodinger	-40.61%	-30.85%	-15.32%

Erasca currently has a consensus target price of $20.11, suggesting a potential upside of 8.89%. Schrodinger has a consensus target price of $20.25, suggesting a potential upside of 19.96%. Given Schrodinger's higher possible upside, analysts clearly believe Schrodinger is more favorable than Erasca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Schrodinger	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Schrodinger beats Erasca on 9 of the 15 factors compared between the two stocks.

How does Schrodinger compare to Kiniksa Pharmaceuticals International?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Schrodinger (NASDAQ:SDGR) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and profitability.

Kiniksa Pharmaceuticals International has higher revenue and earnings than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$677.56M	7.33	$59.01M	$0.90	71.70
Schrodinger	$255.87M	4.87	-$103.26M	-$1.41	N/A

Kiniksa Pharmaceuticals International currently has a consensus target price of $62.71, indicating a potential downside of 2.81%. Schrodinger has a consensus target price of $20.25, indicating a potential upside of 19.96%. Given Schrodinger's higher probable upside, analysts plainly believe Schrodinger is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00
Schrodinger	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. Comparatively, 79.1% of Schrodinger shares are held by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are held by company insiders. Comparatively, 10.1% of Schrodinger shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Kiniksa Pharmaceuticals International had 6 more articles in the media than Schrodinger. MarketBeat recorded 7 mentions for Kiniksa Pharmaceuticals International and 1 mentions for Schrodinger. Schrodinger's average media sentiment score of 1.40 beat Kiniksa Pharmaceuticals International's score of 1.23 indicating that Schrodinger is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kiniksa Pharmaceuticals International	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Schrodinger	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kiniksa Pharmaceuticals International has a beta of 0.07, indicating that its share price is 93% less volatile than the broader market. Comparatively, Schrodinger has a beta of 1.62, indicating that its share price is 62% more volatile than the broader market.

Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to Schrodinger's net margin of -40.61%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat Schrodinger's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%
Schrodinger	-40.61%	-30.85%	-15.32%

Summary

Kiniksa Pharmaceuticals International beats Schrodinger on 13 of the 17 factors compared between the two stocks.

Get Schrodinger News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SDGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SDGR vs. The Competition

Export

Metric	Schrodinger	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.25B	$1.83B	$7.18B	$12.48B
Dividend Yield	N/A	N/A	2.66%	6.51%
P/E Ratio	-11.97	81.75	28.02	24.70
Price / Sales	4.87	7.18	538.99	99.06
Price / Cash	N/A	26.08	49.26	57.09
Price / Book	3.42	5.75	10.96	6.46
Net Income	-$103.26M	-$54.76M	$3.57B	$337.01M
7 Day Performance	0.12%	2.95%	2.12%	1.69%
1 Month Performance	17.39%	2.81%	5.25%	3.81%
1 Year Performance	-19.47%	-0.07%	33.29%	23.90%

Schrodinger Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SDGR Schrodinger	2.7714 of 5 stars	$16.88 flat	$20.25 +20.0%	-19.5%	$1.25B	$255.87M	N/A	790	Positive News
DNTH Dianthus Therapeutics	2.28 of 5 stars	$87.37 +5.9%	$117.82 +34.8%	+393.5%	$4.51B	$2.04M	N/A	80	Gap Down
ORKA Oruka Therapeutics	3.16 of 5 stars	$85.38 +18.0%	$131.30 +53.8%	+576.5%	$4.36B	N/A	N/A	N/A	Analyst Downgrade Gap Up High Trading Volume
MANE Veradermics	0.7491 of 5 stars	$103.05 +9.8%	$114.20 +10.8%	N/A	$4.31B	N/A	N/A	19
ERAS Erasca	1.5414 of 5 stars	$15.08 +10.3%	$20.11 +33.4%	+1,238.4%	$4.25B	N/A	N/A	120	Trending News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SDGR) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Schrodinger (SDGR) Competitors

SDGR vs. DNTH, ORKA, MANE, ERAS, and KNSA

How does Schrodinger compare to Dianthus Therapeutics?

Summary

How does Schrodinger compare to Oruka Therapeutics?

Summary

How does Schrodinger compare to Veradermics?

Summary

How does Schrodinger compare to Erasca?

Summary

How does Schrodinger compare to Kiniksa Pharmaceuticals International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SDGR vs. The Competition

Schrodinger Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Schrodinger (SDGR) Competitors

SDGR vs. DNTH, ORKA, MANE, ERAS, and KNSA

How does Schrodinger compare to Dianthus Therapeutics?

Does the media prefer SDGR or DNTH?

Which has more volatility and risk, SDGR or DNTH?

Is SDGR or DNTH more profitable?

Do analysts prefer SDGR or DNTH?

Which has better valuation & earnings, SDGR or DNTH?

Do insiders and institutionals have more ownership in SDGR or DNTH?

Summary

How does Schrodinger compare to Oruka Therapeutics?

Is SDGR or ORKA more profitable?

Which has more risk & volatility, SDGR or ORKA?

Do analysts rate SDGR or ORKA?

Which has higher earnings and valuation, SDGR or ORKA?

Does the media prefer SDGR or ORKA?

Do insiders & institutionals have more ownership in SDGR or ORKA?

Summary

How does Schrodinger compare to Veradermics?

Is SDGR or MANE more profitable?

Do analysts rate SDGR or MANE?

Do institutionals and insiders have more ownership in SDGR or MANE?

Does the media favor SDGR or MANE?

Which has preferable earnings & valuation, SDGR or MANE?

Summary

How does Schrodinger compare to Erasca?

Which has more risk & volatility, ERAS or SDGR?

Does the media favor ERAS or SDGR?

Do institutionals & insiders hold more shares of ERAS or SDGR?

Which has better valuation and earnings, ERAS or SDGR?

Is ERAS or SDGR more profitable?

Do analysts rate ERAS or SDGR?

Summary

How does Schrodinger compare to Kiniksa Pharmaceuticals International?

Which has preferable earnings and valuation, KNSA or SDGR?

Do analysts rate KNSA or SDGR?

Do institutionals & insiders hold more shares of KNSA or SDGR?

Does the media favor KNSA or SDGR?

Which has more volatility and risk, KNSA or SDGR?

Is KNSA or SDGR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SDGR vs. The Competition

Schrodinger Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools